Article
Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose…
medRxiv · 2021 · Skovso, S.; Panzhinskiy, E.; Kolic, J.; Cen, H. H.; Dionne, D. A.; Dai, X.-Q.; Sharma, R. B.; Elghazi, L.; Ellis, C. E.; Faulkner, K.; Marcil, S. A. M.; Overby, P.; Noursadeghi, N.; Hutchinson, D.; Hu, X.; Modi, H.; Wildi, J.; Botezelli, J. D.; Noh, H. L.; Suk, S.; Gablaski, B.; Bautista, A.; Kim, R.; Cras-Meneur, C.; Flibotte, S.; Sinha, S.; Luciani, D. S.; Nislow, C.; Rideout, E. J.; Cytrynbaum, E. N.; Kim, J.; Bernal-Mizrachi, E.; Alonso, L. C.; MacDonald, P. E.; Johnson, J. D.
Key facts
| Title | Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance |
|---|---|
| First author | Skovso, S.; Panzhinskiy, E.; Kolic, J.; Cen, H. H.; Dionne, D. A.; Dai, X.-Q.; Sharma, R. B.; Elghazi, L.; Ellis, C. E.; Faulkner, K.; Marcil, S. A. M.; Overby, P.; Noursadeghi, N.; Hutchinson, D.; Hu, X.; Modi, H.; Wildi, J.; Botezelli, J. D.; Noh, H. L.; Suk, S.; Gablaski, B.; Bautista, A.; Kim, R.; Cras-Meneur, C.; Flibotte, S.; Sinha, S.; Luciani, D. S.; Nislow, C.; Rideout, E. J.; Cytrynbaum, E. N.; Kim, J.; Bernal-Mizrachi, E.; Alonso, L. C.; MacDonald, P. E.; Johnson, J. D. |
| Journal | medRxiv |
| Published | Jul 19, 2021 |
| DOI | 10.1101/2020.10.15.338160 |
| Devices mentioned | K021943, K040782, K043197, K053529, K061118, K072543, K073231, K081318, K082513, K120558, K132618, K781337 and 37 more |
| Product codes mentioned | CDD, CDP, CDX, CEC, CFP, CGN, CGR, CJM, CKG, DBM, JJH, JLW and 21 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1